ABSTRACT The recent progress in sequencing technologies makes possible large-scale medical sequencing efforts to assess the importance of rare variants in complex diseases. The results of such efforts depend heavily on the use of efficient study designs and analytical methods. We introduce here a unified framework for association testing of rare variants in family-based designs or designs based on unselected affected individuals. This framework allows us to quantify the enrichment in rare disease variants in families containing multiple affected individuals and to investigate the optimal design of studies aiming to identify rare disease variants in complex traits. We show that for many complex diseases with small values for the overall sibling recurrence risk ratio, such as Alzheimer's disease and most cancers, sequencing affected individuals with a positive family history of the disease can be extremely advantageous for identifying rare disease variants. In contrast, for complex diseases with large values of the sibling recurrence risk ratio, sequencing unselected affected individuals may be preferable.
C OMMON diseases such as diabetes, cancer, and autism are likely caused by a complex interaction among many genes and environmental factors. Both common and rare genetic variants are expected to play a role. Thus far the available technology has allowed for the identification of common disease susceptibility variants, mostly via genomewide association studies. However, the common variants detected so far have small effect sizes and overall explain only a small fraction of the estimated trait heritability (Maher 2008; Manolio et al. 2009 ). The recent advances in nextgeneration sequencing technologies (Metzker et al. 2010; Tucker et al. 2009 ) allow for the first time an objective assessment of the importance of rare variants in complex diseases. An increasing number of recent studies on hypertension, schizophrenia, epilepsy, type-1 diabetes, autism, etc. (Ji et al. 2008; Stefansson et al. 2008; Helbig et al. 2009; Nejentsev et al. 2009; Pinto et al. 2010) implicate rare variants in these disorders.
Ongoing sequencing studies are already generating unprecedented amounts of genetic data. The large number of genetic variants in these data sets, most of them with low frequencies (,1%), creates great challenges for statistical analysis. Traditional association testing strategies that have worked well for common variants will have low power to identify rare disease susceptibility variants (Morris and Zeggini 2009; Bansal et al. 2010) . To extract the rich information provided by large sequencing data sets, several novel statistical approaches have been proposed, especially designed to identify rare variants that influence disease risk (Li and Leal 2008; Madsen and Browning 2009; Bhatia et al. 2010; Han and Pan 2010; King et al. 2010; Liu and Leal 2010; Price et al. 2010; Ionita-Laza et al. 2011; Neale et al. 2011) . The common idea underlying all these methods is to group variants in a region of interest, e.g., a gene, and perform a gene-based test rather than individual tests for each of the variants in a gene.
An important question that has not yet been addressed is the relative power of designs based on affected relatives vs. designs using unselected affected individuals to identify rare disease variants. Since rare disease variants tend to be enriched in families containing multiple affected individuals, family-based designs can play an important role in the identification of rare causal variants. The purpose of this article is to quantify this enrichment and to study its implications for the optimal design of studies that search for rare disease variants in complex traits.
Methods

Effective number of variants in related individuals
By analogy to the concepts of "effective population size" in population genetics (Wright 1931 (Wright , 1938 and "effective number of markers" in a linkage disequilibrium block (Nyholt 2004) , we introduce here a new concept for analysis of rare variants in related individuals: the effective number of variants at a position, i.e., the number of "independent" variants at a specific position in a sample of related individuals. More precisely, the effective number of variants is the number of observed variants corrected for the known familial correlation among the individuals included in a sample. This concept is important as it allows a uniform comparison of designs based on various types of relatives, regardless of the relationship type.
For simplicity of presentation we define the effective number of variants at a position for a pair of individuals. If the individuals are unrelated, then the effective number of variants is equal to the observed number of variants since the two individuals are independent (hence no correction is necessary). However, the effective number of variants in related individuals is less than the total number of observed variants if some of the variants are shared among family members. For example, for a pair of siblings each of whom carries a rare variant in heterozygous state at a position, the effective number of variants will be less than the observed number of variants, i.e., two, due to the high probability that these two variants are shared identical-by-descent (IBD) and hence are not independent. Similarly, for a pair of second cousins that each carry a rare variant in heterozygous state the effective number of variants is less than two, although as shown in the examples below, it is higher than for a pair of siblings due to the lower likelihood that a variant is shared IBD for second cousins compared with siblings. Below we define mathematically the concept of effective number of variants.
For a pair of relatives we define the effective number of variants, k eff , as follows:
k effj2 if both relatives carry a rare variant k effj1 if only one of the two relatives carries a rare variant k effj0 if neither of the two relatives carries a rare variant:
By definition, k eff|1 = 1 and k eff|0 = 0. For k eff|2 , we show in supporting information, File S1 that
where f is the frequency of the variant, and u is the kinship coefficient; d = 0 if the two relatives can share a maximum of one allele IBD (e.g., first cousins) and 1 if they can share two alleles IBD (e.g., siblings). The approximation is based only on the assumption that the variant is rare (i.e., f # 0.01) and is very accurate under this assumption. When the two individuals are unrelated and each carries a rare variant, u = 0 and we obtain the expected result that k eff|2 = 2. For identical twins u = 0.5, d = 1, and k eff|2 = 1. For relatives in between, the effective number of variants is between 1 and 2. For two sibs, u ¼ 1 4
, d = 1, and hence for f = 0.01 we obtain k eff|2 = 1.17. Similarly for two second cousins, u ¼ 1 64
, d = 0, and hence k eff|2 = 1.76. These and other examples are summarized in Table 1 . Note that the effective number of variants depends on the frequency f. Hence, as expected, the lower the frequency is, the lower the effective number of variants, reflecting the low probability that these shared variants are independent (and the greater chance they are identical-by-descent).
To summarize, for a pair of relatives k eff is calculated as follows: Under the assumption that the variant is not associated with disease, we calculate the expected value of k eff for a pair of relatives in File S1 (Equation S7) as
At a rare variant position, for a data set of relative pairs of the same type in N different families, we define k
eff is the effective number of variants in family i. Then
If the variant is not associated with disease, then the distribution of k At a disease locus, the effective number of variants in two affected relatives is expected to be increased compared to a nondisease locus. We consider here a two-locus genetic heterogeneity model (Risch 1990a) , where each locus is an independent cause for disease. We use the two-locus model for mathematical convenience; without loss of generality the second locus can be considered to encompass all the other disease loci that act additively to influence disease risk, in addition to the primary locus under investigation. The effective number of variants we expect to observe at the first disease locus in a pair of affected relatives is I. Ionita-Laza and R. Ottman
where b R , a R $ 1 are derived in File S1 and depend on the type of relationship R (e.g., sibs, first cousins, etc.), the genotype relative risk (GRR) for the first locus, and the overall recurrence risk in siblings as measured by l S (Risch 1990a For a data set of N different families, each consisting of an affected relative pair of the same type, we have
As above, the distribution of k
can be approximated by a Poisson distribution with mean E½k D;Total eff (as also shown empirically File S1).
Furthermore, using Equation 4 we can also calculate the effective number of variants we expect at the first disease locus in an affected individual with an affected relative. This is important to evaluate the importance of selecting affected individuals with a positive family history for a disease for inclusion in a sequencing study. We denote by k D 1 the number of variants at the first locus in an affected individual that is known to have an affected relative. Then using Equation 4,
where b R , a R $ 1 are derived in File S1. As above, E½k 
Þ.
Note that the description above pertains to a disease locus with only one disease variant position. However, a disease locus may have multiple disease variant positions (i.e., allelic heterogeneity). The extension to this scenario is straightforward by summing the effective number of variants at each position and using the fact that a sum of independent Poisson random variables is also a Poisson random variable (we assume independence among the different variant positions within a locus, a reasonable approximation given the low frequency of the variants).
Expected P-value at a disease locus
To compare the power of designs on the basis of biologically related cases vs. unrelated cases, we calculate an expected Pvalue (EPV) (Dempster and Schatzoff 1965; Sackrowitz and Samuel-Cahn 1999) . The expected P-value, or expected significance level as originally defined in the pioneering article of Dempster and Schatzoff (1965) , has been proposed as a measure of the performance of a test. Unlike the power of a test, the EPV does not depend on any prespecified significance level and is in close connection with the common practice of reporting P-values in applied research. The EPV is a single number that can be used to judge the performance of a test; the smaller the EPV is, the better the test.
For our situation, the effective number of variants under the null hypothesis that neither of the two loci is associated with disease, k . Then by definition the expected P-value for the first disease locus is
where T 1 $ Poisson(l 1 ) and T 2 $ Poisson(l 2 ). Since the difference between two independent Poisson random variables follows a Skellam distribution (Skellam 1946) , we can calculate the EPV under a disease model only on the basis of the values of l 1 and l 2 .
For comparison we also report results based on power, and, as shown below, they are highly correlated with those based on the EPV. Since we assume that the variant frequency in controls is known, the resulting power levels can be considered as achievable as the number of controls grows very large.
Results
Performance of affected relatives vs. unrelated affected individuals
For identifying rare disease variants, it is of great interest to study the circumstances where study designs involving affected individuals from families containing multiple affected individuals are advantageous compared with those involving unselected affected individuals. Under the assumption of a complex polygenic model, with many possible disease loci each with a small population attributable risk (Risch and Merikangas 1996) , the twolocus disease model can be viewed as consisting of a locus of interest and a second locus accounting for the residual effect. We assume five study designs, each with the same number of affected individuals (i.e., 2000): affected sibpairs, affected first-cousin pairs, affected second-cousin pairs, unrelated affected individuals, and unrelated affected individuals known to have an affected sibling. We consider a complex trait with prevalence 0.03 and a sibling recurrence risk ratio (l S ) between 2 and 10, as observed for many complex traits (Merikangas and Risch 2003) . We assume that the variant frequency at the first disease locus is low, between 0.0001 and 0.01, and several possible values for the genotype relative risk with higher GRRs are assumed for lower frequency at the disease locus. In Figure 1 we show expected P-values associated with the first locus as a function of the sibling recurrence risk ratio, for each of the five study designs.
For complex diseases with low values for l S (e.g., 2-4), affected individuals known to have an affected sibling are extremely advantageous to identify rare disease variants of moderate to large effect (e.g., GRR $ 5-10, Figure 1) . The difference between using affected individuals with an affected sibling vs. unselected affected individuals can be substantial in this case. For example, for a disease with l S = 2, for a locus with frequency 0.001 and a GRR of 5.5 the expected P-value is 10 27.65 for a study with 2000 unrelated affected individuals known to have an affected sibling and only 10 23.77 for a study with 2000 unselected affected individuals. Similarly, for a locus with frequency 0.0001 and a GRR of 14 the corresponding expected P-values are 10 27 and 10 218 . For small values of l S and large values of GRR (e.g., l S = 2 and GRR = 14), even a design based on 1000 affected individuals known to have an affected sibling is expected to be more advantageous than a design based on 2000 unselected affected individuals (Figures 1 and 4) . Similar results are obtained when the design comparison is based on power rather than expected P-value ( Figure S2 ).
However, for complex diseases with larger values of l S such as autism (l S % 22), the advantage of using familybased designs (either affected relative pairs or affected individuals with a known affected sibling) diminishes, and unselected affected individuals can be more advantageous (Figure 2 and Figure S3 ). This trend of greater advantage with unselected affected individuals is more pronounced Figure 1 The effect of locus frequency, GRR, and overall l S on the relative performance (as measured by the expected P-value) of affected relatives vs. unrelated affected individuals. The three rows correspond to three different frequencies for the disease locus: 0.01, 0.001, and 0.0001. l S is between 2 and 10. The number of affected individuals is 2000: 1000 sib-pairs, 1000 first-cousin pairs, 1000 second-cousin pairs, 2000 unrelateds, and 2000 unrelated individuals known to have an affected sibling (i.e., unrelateds+).
with increasing frequency of disease-causing variants (Figure 1) . These results are in concordance with those in Risch (1990b Risch ( , 1992 for linkage analysis, which state that for small values of overall l S and polymorphic information content (PIC) (Botstein et al. 1980) 
Above we have assumed that the disease locus has only one disease variant position. Although this is clearly a simplified scenario, the results obtained are informative for the more realistic scenario when the locus of interest contains multiple disease variants. In Figure 3 we show the results for the case when 5 different disease variant positions are present at the locus. Two cases are illustrated: (1) the GRRs for the individual variants are a decreasing function of frequency, so that lower-frequency variants have substantially higher GRRs compared to more frequent variants (for example, f = 0.0001 and GRR = 21 vs. f = 0.01and GRR = 1.2), and (2) the GRR is the same for all variants (i.e., 2). As can be seen, for the first case, due to the presence of high-risk low-frequency variants among the 5 disease variants, unrelated affected individuals that are known to have an affected sibling are best for small values of l S (as also shown previously in Figure 1 ), whereas for the second case where the GRR for low-frequency variants is modest (i.e., 2), distantly related affected individuals, and in particular unselected affected individuals, perform better. Also shown are results when 10 additional random variants are added to the region. In this case, the relative performance of Figure 2 Usefulness of sequencing both affected individuals in a pair of affected relatives. The three rows correspond to three different frequencies for the disease locus: 0.01, 0.001, and 0.0001. The number of affected individuals is 2000 for the two affected relatives design, i.e., 1000 sib-pairs and 1000 second-cousin pairs, and only 1000 for the design based on only one affected individual in a pair, i.e., 1000 affected individuals known to have an affected sibling and 1000 affected individuals known to have an affected second cousin. Figure 3 Results are shown for scenarios where multiple (i.e., 5) disease susceptibility variants (DSVs) are present at the disease locus. The relationship between the GRR and disease variant frequency is shown in the first column. In the top panel, the GRR is a decreasing function of variant frequency, while in the bottom panel, the GRR is the same (i.e., 2) regardless of variant frequency. The third column presents results when 10 additional random variants (i.e., not disease variants) are also present. different designs is unchanged, but the performance is reduced for all designs.
The utility of sequencing both affected individuals in a pair of affected relatives Sequencing both individuals from a pair of affected relatives doubles the sequencing costs, so it is important to consider the circumstances under which power is increased by this approach. We evaluated the utility of sequencing both affected individuals in an affected relative pair compared to sequencing only one individual from the pair (Figure 4 and Figure S4 ). We find that for affected sibling pairs, sequencing the second sibling contributes little additional information; hence sequencing only one of two affected siblings is expected to be on average almost as good as sequencing both of them, with the significant advantage of reducing the sequencing cost by half (Figure 4) . However, for more distantly related individuals, such as second cousins, sequencing both individuals is expected to be more powerful than sequencing only one of them. The advantage can be significant. For example, when l S = 2, for a locus with frequency 0.001 and a GRR of 5.5 the expected P-value is 10 24 for a study with 1000 affected second-cousin pairs (power at a = 1.6 · 10 26 is 87%) and only 10 22.1 for a study with 1000 affected individuals known to have a second cousin affected (power is 47%). If instead we compare the power of a study with 1000 affected second-cousin pairs with that of a study with 2000 affected individuals known to have a second cousin affected, hence the same sequencing cost for both studies, we find that the power levels are very similar (data not shown).
Discussion
In complex diseases characterized by extensive genetic heterogeneity, each disease locus is likely to be responsible for a very small fraction of affected individuals in a population. The choice of the affected individuals to be included in a study greatly influences the power to identify disease loci. The framework developed here, based on the effective number of variants in a pair of affected relatives, makes it feasible to quantify the enrichment in rare disease variants in family-based vs. population-based samples and to investigate the optimal study design for identifying rare disease variants in complex traits.
We have shown here that for diseases with small values for the sibling recurrence risk ratio, as observed with many complex traits, sequencing affected individuals with an affected close relative, such as a sibling, can be an extremely powerful strategy for identifying rare disease variants with moderate to large GRRs. This finding is in concordance with Figure 4 For complex traits with a large value for l S (e.g., l S = 22 for autism) we show expected P-values for a disease locus with frequency f = 0.001 as a function of the GRR for five study designs, each with 2000 affected individuals: 1000 sib-pairs, 1000 first-cousin pairs, 1000 second-cousin pairs, 2000 unrelateds, and 2000 unrelated individuals known to have an affected sibling (i.e., unrelateds+).
previous findings for breast cancer and common variants (Antoniou and Easton 2003) . However, we find that the advantage of using affected individuals with a positive family history declines with increasing values of l S. For complex diseases with large values of l S , such as autism (l S % 22), unselected affected individuals may be preferable. The main explanation for these results is that for a complex disease involving many contributing disease loci, one single locus is likely to explain less of the overall familial aggregation when l S is large than when l S is small. Hence when l S is large, focusing on affected relatives (or individuals with an affected relative) may enrich the sample in rare disease loci that are less likely to be shared among multiple families, and therefore unselected affected individuals may be preferable.
Designs based on affected relative pairs are commonly employed in linkage analysis (Weeks and Lange 1988) . Although here we have not attempted to examine the performance of linkage analysis, we note that the results we obtained agree well with those for linkage analysis (Risch 1990b (Risch , 1992 , which state that for small values of overall l S and disease locus frequency affected sib-pairs are optimal, while for large values of l S and disease locus frequency, more distantly related individuals are best.
The framework developed here is important for the statistical analysis of rare variant data. We have introduced here the concept of effective number of variants at a position in a set of relatives, which allows for a unified treatment of both biologically related and unrelated affected individuals and makes feasible natural extensions of statistical tests recently developed for population-based designs (such as the weighted-sum statistic in Madsen and Browning 2009) to general designs based on affected relative pairs and/or unrelated affected individuals. One simple statistic for affected relative pairs would be a weighted sum of the effective number of variants at different positions. Such extensions are currently under development.
The main goal of this article is to introduce a framework to assess the enrichment of rare disease mutations in affected relative pairs of different types. Such an enrichment analysis is of relevance for any association testing method, and therefore the results presented are expected to be valid in general for association testing. We have applied this framework to the problem of optimal study design for association studies with rare variants.
Software implementing the described methods is available in File S2, as well as on the first author's webpage at http://www.columbia.edu/~ii2135/, and should be helpful in the design of association studies with rare variants. 
GENETICS
Supplemental Material
S1 Effective number of variants in related individuals
We derive here in detail the results in the text, in particular relations (1) and (2).
Assumption S1. We assume for simplicity that all individuals who carry a rare variant are in fact heterozygous. This assumption is reasonable for our setting since homozygous genotypes would have very low probability for rare variants (f 2 ≤ 10 −4 for f ≤ 0.01).
We are interested in computing the joint distribution of the genotypes at a position in two related individuals. Let us code the genotype of an individual as 0, 1 or 2, denoting the number of rare variants (or minor alleles) in the genotype. For example, a homozygous genotype for the rare variant is denoted by 2 (however, we ignore individuals with genotype 2 by Assumption S1).
Claim S2. Let p {i,j} be the probability that the genotypes in two related individuals are i and j, with i, j ∈ {0, 1}. Let ϕ be the kinship coefficient for the two relatives, f be the minor allele frequency at a variant position, and δ be 1 if the two relatives can share two alleles IBD, and 0 if the two relatives can share a maximum of one allele IBD. Then the following relationships are true:
Table S-1: Joint probabilities for the genotypes in two related individuals.
Proof. To calculate p {i,j} we condition on the IBD sharing between the two individuals. There are at most two alleles that can be shared IBD between two individuals, depending on the precise relationship. Let p ij|k be the probability that in a set of relatives the first genotype is i and the second genotype is j conditional on the IBD sharing being k, where i, j ∈ {0, 1} and 0 ≤ k ≤ 2. We now calculate the probabilities p ij|k in turn.
-IBD sharing is 0 with probability
Because the genotypes at the two relatives are independent in this case it is relatively easy to calculate p ij|0 (Table S-2) .
The results in the table are based on multiplying the probabilities of individual genotypes. For example, p 01|0 = P (genotype 1 is 0 and genotype 2 is 1|
Genotype 2 Genotype 1 0 1 Table S -2: Joint probabilities for the genotypes in two related individuals, conditional on the IBD sharing being 0, i.e., p ij|0 .
-IBD sharing is 1 with probability
Results for p ij|1 are in Table S-3. Genotype 2 Genotype 1 0 1
Table S-3: Joint probabilities for the genotypes in two related individuals, conditional on the IBD sharing being 1, i.e., p ij|1 .
The results in the table are calculated as follows:
p 00|1 = P (genotype 1 is 0 and genotype 2 is 0| IBD = 1) = = P (genotype 1 is 0| genotype 2 is 0 and IBD = 1)P ( genotype 2 is 0|IBD = 1) =
Also p 10|1 = P (genotype 1 is 1 and genotype 2 is 0| IBD = 1) = = P (genotype 1 is 1| genotype 2 is 0 and IBD = 1)P ( genotype 2 is 0|IBD = 1
Similarly p 11|1 = P (genotype 1 is 1 and genotype 2 is 1| IBD = 1) = = P (genotype 1 is 1| genotype 2 is 1 and IBD = 1)P ( genotype 2 is 1|IBD = 1) =
Genotype 2 Genotype 1 0 1
Table S-4: Joint probabilities for the genotypes in two related individuals, conditional on the IBD sharing being 2, i.e., p ij|2 .
-IBD sharing is 2 with probability
In this case, the two genotypes are identical. Results for p ij|2 are in Table S -4.
It is relatively easy to derive the results in the table. For example:
p 11|2 = P (genotype 1 is 1 and genotype 2 is 1| IBD = 2) = = P (genotype 1 is 1| genotype 2 is 1 and IBD = 2)P (genotype 2 is 1|IBD = 2) = = 1 · 2f (1 − f ) = 2f (1 − f ).
From Tables S-2, S-3 and S-4 we get:
p {0,0} = P (genotype 1 is 0 and genotype 2 is 0) =
p {0,1} = P (genotype 1 is 0 and genotype 2 is 1 OR genotype 1 is 1 and genotype 2 is 0) = = 2P (genotype 1 is 0 and genotype 2 is 1) = = 2(p 01|0 P (
p {1,1} = P (genotype 1 is 1 and genotype 2 is 1) =
Using simple algebraic manipulation it is possible to simplify the above expressions for p {0,0} , p {0,1} , and p {1,1} (Table S-5) . 
Table S-6: Joint probabilities for the genotypes in two unrelated individuals (ϕ = 0, δ = 0). 
Proof. We define the effective number of variants in a pair of individuals that are both heterozygous, denoted by k eff|2 , to satisfy the equation:
P (genotype 1 is 1 and genotype 2 is 1|neither genotype is 2) = = P (genotype 1 is 1|genotype 1 is not 2) k eff|2 .
When the two individuals are unrelated we can see that k eff|2 should be 2. Similarly, when the two individuals are identical twins k eff|2 should be 1, as expected. In order to define k eff|2 we need to calculate first the probability that two relatives are both heterozygous, given that they are not homozygous (as by Assumption S1). More precisely, for a pair of relatives we have: P (genotype 1 is 1 and genotype 2 is 1|neither genotype is 2) = = P (genotype 1 is 1 and genotype 2 is 1)
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In the approximation above, we approximate
01. These approximations are very good, and have only negligible effect.
Also the probability that an individual is heterozygous, conditional on not being homozygous is:
if we assume that 1 + f ∼ = 1 for f ≤ 0.01. As can be seen, the conditioning on the genotype not being 2 has negligible effect, so we will ignore it in subsequent calculations. By definition the effective number of variants in a pair of individuals that are both heterozygous, denoted by k eff|2 , satisfies the equation: P (genotype 1 is 1 and genotype 2 is 1|neither genotype is 2) = = P (genotype 1 is 1|genotype 1 is not 2) k eff|2 .
Using the relationships above we get:
Note that the above approximation is extremely good. It is easy to see that for two unrelated individuals, since ϕ = 0 and δ = 0, we get k eff|2 = 2; for two identical twins, since ϕ = 0.5 and δ = 1 we get k eff|2 = 1. These values match our intuition, namely, that for unrelated individuals the two variants are indepedent, while for identical twins there is only one independent variant.
If only one of the two relatives carries a rare variant, then the effective number of variants in the pair, denoted by k eff|1 , is 1. Similarly, if neither of the two relatives is carrier of rare variant, then k eff|0 = 0. For a pair of relatives we calculate the effective number of variants, denoted by k eff , as follows:
if both relatives carry a rare variant k eff|1 if only one of the two relatives carries a rare variant k eff|0 if neither of the two relatives carries a rare variant Using the derivations above, we can now calculate the effective number of variants expected at a variant position in a pair of individuals:
S2 Effective number of variants in affected relatives at a disease locus
In a similar fashion, we can also calculate the effective number of variants we expect to observe at a disease locus, and derive relation (4) in text. We assume a two-locus genetic heterogeneity model, with either locus being an independent disease cause. Similar to the derivations above we calculate p D {i,j} , i.e., the probability that two affected relatives have genotypes i and j at the first disease locus, with i, j ∈ {0, 1}. Using Bayes rule we obtain:
p {i,j} P (two affected | the two genotypes at the first disease locus are i and j) P (two affected relatives) .
If we let K be the disease prevalence, and K R be the risk to a type R relative of an affected individual, then it is true that:
In order to compute P (two affected relatives| the two genotypes at the first disease locus are i and j), we need to introduce some notation. Risch (1990a) . Let x i and y j be the marginal "penetrance summands" at the two disease loci in our two-locus model, defined such that the penetrance w ij = 1 − (1 − x i )(1 − y j ); i and j index the possible genotypes at the two loci with 0 ≤ i ≤ 2, and 0 ≤ j ≤ 2. Let p i and q j be the population frequencies of those genotypes, and τ jk be the conditional probability that the relative has genotype k given that the proband has genotype j. K 1 and K 2 are the prevalences for the two disease loci; K 1R and K 2R are the recurrence risks in relatives corresponding to the two disease loci.
Notation. We follow closely the notations in
Then the following relationships hold (see Risch 1990a):
With these notations, we can now show how to derive P (two affected relatives| the two genotypes at the first disease locus are 1 and 1). P (two affected relatives| the two genotypes at the first disease locus are 1 and 1) =
If we let
Note that β R = 1 when neither of the two-loci is involved in disease. Similarly, we can calculate P (two affected relatives| the two genotypes at the first disease locus are 0 and 1). Note that α R = 1 when neither of the two-loci is involved in disease.
For one pair of affected relatives the effective number of rare variants we expect to observe at the first disease locus is:
i.e., relation (4) , with a GRR of 1 − 4 and frequency of 0.001 − 0.01 in a dataset of 1000 affected sib-pairs, or 2000 unrelated affected individuals, with λ S = {2, 4}. A two-locus disease heterogeneity model is assumed. Results based on analytical calculations (A) -using eq. (4) in text or eq. (S10) in Supplemental Material S2 -and 10000 simulated datasets (S) are shown.
S4 Locus specific recurrence risk to siblings
In Supplemental Table S-9 for each of the disease variants in Figure 1 we report the locus specific recurrence risk to siblings (λ 1S ). Table S-9: The locus specific λ S for the disease variants in Figure 1 .
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